Millipore Sigma Vibrant Logo

579051 TAPI-1 - CAS 171235-71-5 - Calbiochem

Descripción

Replacement Information

Tabla espec. clave

CAS #Empirical Formula
171235-71-5C₂₆H₃₇N₅O₅

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
579051-1MG
Comprobando disponibilidad...
Disponibilidad a confirmar
Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      Ampolla de plást. 1 mg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      Solicitar precio
      Description
      OverviewA structural analog of TAPI-0 (Cat. No. 579050) with similar in vitro efficacy for the inhibition of MMPs and TACE (TNF-α converting enzyme/ADAM17). TAPI-1 also blocks the shedding of several cell surface proteins such as IL-6 receptor, p60 TNF receptor, and p80 TNF receptor. Blocks constitutive (IC50 = 8.09 µM) and muscarinic receptor-stimulated (IC50 = 3.61 µM) sAAPα release in HEK 293 cells expressing M3 muscarinic receptors. A 10 mM (500 µg/100 µl) solution of TAPI-1 (Cat. No. 579050) in DMSO is also available.
      Catalogue Number579051
      Brand Family Calbiochem®
      SynonymsN-(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-naphthylalanyl-L-alanine, 2-aminoethyl Amide, TNF-α Protease Inhibitor-1
      References
      ReferencesSlack, B.E., et al. 2001. Biochem. J. 357, 787.
      Vincent, B., et al. 2001. J. Biol. Chem. 276, 37743.
      Hooper, N.M., et al. 1997. Biochem. J. 321, 265.
      Crowe, P.D., et al. 1995. J. Exp. Med. 181, 1205.
      Mullberg, J., et al. 1995. J. Immunol. 155, 5198.
      Mohler, K.M., et al. 1994. Nature 370, 218.
      Product Information
      CAS number171235-71-5
      ATP CompetitiveN
      DeclarationManufactured exclusively by Peptides International, Louisville, Kentucky, USA.
      FormWhite solid
      Hill FormulaC₂₆H₃₇N₅O₅
      Chemical formulaC₂₆H₃₇N₅O₅
      Hygroscopic Hygroscopic
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetMMPs and TACE
      Primary Target IC<sub>50</sub>8.09 µM and 3.61 µM blocking constitutive and muscarinic receptor-stimulated sAAPα release in HEK 293 cells expressing M3 muscarinic receptors, respectively
      Purity≥97% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      579051-1MG 04055977265361

      Documentation

      Licencias necesarias

      Título
      CARTA DE USO GENERAL 2016
      PRODUCTO REGULADO POR LA SECRETARÍA DE SALUD

      TAPI-1 - CAS 171235-71-5 - Calbiochem Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      TAPI-1 - CAS 171235-71-5 - Calbiochem Certificados de análisis

      CargoNúmero de lote
      579051

      Referencias bibliográficas

      Visión general referencias
      Slack, B.E., et al. 2001. Biochem. J. 357, 787.
      Vincent, B., et al. 2001. J. Biol. Chem. 276, 37743.
      Hooper, N.M., et al. 1997. Biochem. J. 321, 265.
      Crowe, P.D., et al. 1995. J. Exp. Med. 181, 1205.
      Mullberg, J., et al. 1995. J. Immunol. 155, 5198.
      Mohler, K.M., et al. 1994. Nature 370, 218.

      Citas

      Título
    • Daniel W. Lambert, et al. (2005) Tumor Necrosis Factor- Convertase (ADAM17) Mediates Regulated Ectodomain Shedding of the Severe-acute Respiratory Syndrome-Coronavirus (SARS-CoV) Receptor, Angiotensin-converting Enzyme-2 (ACE2). Journal of Biological Chemistry 280, 30113-30119.
    • Daniel W. Lambert, et al. (2005) Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the SARS-CoV receptor, angiotensin-converting enzyme-2 (ACE2). Journal of Biological Chemistry 280, 30113-30119.
    • Xu-Wen Liu, et al. (2005) Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Research 65, 898-906.
    • Evelyn Roth and Hanspeter Pircher. (2004) IFN-γ promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells. Journal of Immunology 172, 1588-1594.
    • Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision04-April-2011 RFH
      SynonymsN-(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-naphthylalanyl-L-alanine, 2-aminoethyl Amide, TNF-α Protease Inhibitor-1
      DescriptionA structural analog of TAPI-0 (Cat. No. 579050) with similar in vitro efficacy for the inhibition of MMPs and TACE (TNF-α convertase; ADAM17). However, TAPI-1 is more stable in serum than TAPI-0. TAPI-1 Blocks the shedding of several cell surface proteins such as TNF-α, IL-6 receptor, and p60 and p80 TNF receptors. Inhibits constitutive (IC50 = 8.09 µM) and muscarinic receptor-stimulated (IC50 = 3.61 µM) sAPPa release in HEK-293 cells expressing muscarinic receptors. Also blocks the TACE-dependent constitutive release of co-transfected APP(695) (IC50 = 920 nM).
      FormWhite solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number171235-71-5
      Chemical formulaC₂₆H₃₇N₅O₅
      Structure formulaStructure formula
      Purity≥97% by HPLC
      SolubilityDMSO (5 mg/ml) or Methanol (1 mg/ml)
      Storage Protect from light
      -20°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
      Toxicity Standard Handling
      ReferencesSlack, B.E., et al. 2001. Biochem. J. 357, 787.
      Vincent, B., et al. 2001. J. Biol. Chem. 276, 37743.
      Hooper, N.M., et al. 1997. Biochem. J. 321, 265.
      Crowe, P.D., et al. 1995. J. Exp. Med. 181, 1205.
      Mullberg, J., et al. 1995. J. Immunol. 155, 5198.
      Mohler, K.M., et al. 1994. Nature 370, 218.
      Citation
    • Daniel W. Lambert, et al. (2005) Tumor Necrosis Factor- Convertase (ADAM17) Mediates Regulated Ectodomain Shedding of the Severe-acute Respiratory Syndrome-Coronavirus (SARS-CoV) Receptor, Angiotensin-converting Enzyme-2 (ACE2). Journal of Biological Chemistry 280, 30113-30119.
    • Daniel W. Lambert, et al. (2005) Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the SARS-CoV receptor, angiotensin-converting enzyme-2 (ACE2). Journal of Biological Chemistry 280, 30113-30119.
    • Xu-Wen Liu, et al. (2005) Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Research 65, 898-906.
    • Evelyn Roth and Hanspeter Pircher. (2004) IFN-γ promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells. Journal of Immunology 172, 1588-1594.